Our complex generics engine, particularly in respiratory, has matured into a key growth driver
Why continuous learning is the lifeblood of the pharmaceutical industry
Why India Needs A New Playbook For TB Elimination
We are expanding our CDMO capabilities to meet the next wave of complex therapies starting with oncology
Integrating ESG Performance into Long-Term Capital Strategy for Indian Pharma
Redrawing the Biopharma Map: India’s Rise in the Biosimilars Era
Vice President and Global Head – Corporate Communications
